Breaking News

MilliporeSigma Breaks Ground on U.S. Production Facility

New facility to manufacture Hi-Flow Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, broke ground at its Sheboygan, WI site, for the company’s first lateral flow membrane production facility in the U.S. Lateral flow membranes are a key component in rapid diagnostic test kits for a variety of applications, including Covid-19 testing. The new facility is supported by a $136.7 million contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters